External-beam radiation therapy (EBRT) use and safety with Radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

P. Stroelin,Joe M. O’Sullivan,Oliver Sartor,Chris Parker,Peter Hoskin,Anders Widmark,B. Mellado,Svein Inge Helle,Anne-Kirsti Aksnes,J. Garcia-Vargas,Sten Nilsson

External-beam radiation therapy (EBRT) use and safety with Radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

2015

P. Stroelin
Joe M. O’Sullivan
Oliver Sartor
Chris Parker
Peter Hoskin
Anders Widmark
B. Mellado
Svein Inge Helle
Anne-Kirsti Aksnes
J. Garcia-Vargas
Sten Nilsson

External-beam radiation therapy (EBRT) use and safety with Radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

Keywords:

Prostate cancer
Castration
Radium-223 Dichloride
Oncology
Radiation therapy
Medicine
Internal medicine
external beam radiation
in patient
castration resistant

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations